kek
Contracts For Feb. 14, 2022
ARMY
Eli Lilly and Co., Indianapolis, Indiana, was awarded a $1,080,000,000 firm-fixed-price contract for manufacture, distribution and storage of Bebtelovimab in support of the national emergency response to COVID-19. Bids were solicited via the internet with one received. Work will be performed in Indianapolis, Indiana, with an estimated completion date of Jan. 31, 2023. Health and Human Services Biomedical Advanced Research and Development Authority (HHS/BARDA) American Rescue Plan Act funds in the amount of $1,080,000,000 were obligated at the time of the award. U.S. Army Contracting Command, Aberdeen Proving Ground, Maryland, is the contracting activity (W58P05-22-C-0012). (Awarded Feb. 10, 2022)
https://www.defense.gov/News/Contracts/Contract/Article/2934697/
FDA approved Bebtelovimab on Friday, billion dollar Eli Lilly DOD contract Monday
Coronavirus (COVID-19) Update: FDA Authorizes New Monoclonal Antibody for Treatment of COVID-19 that Retains Activity Against Omicron Variant
February 11, 2022
Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for a new monoclonal antibody for the treatment of COVID-19 that retains activity against the omicron variant. The EUA for bebtelovimab is for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms, which is about 88 pounds) with a positive COVID-19 test, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate.
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-new-monoclonal-antibody-treatment-covid-19-retains